Pituitary and ovarian suppression after early follicular and midluteal administration of a lhrh agonist in a depot formulation: Decapeptyl cr

F. J. Broekmans*, R. E. Bemardus, G. Berkhout, J. Schoemaker

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Scopus)

Abstract

In order to study its effect on pituitary and ovarian function, a single dose of triptorelin depot (Decapeptyl CR® Ferring) was administered to 12 women in the early follicular (EF, n=6) or midluteal phase (ML, n=6) of a normal cycle. In all 12 women the initial pituitary and ovarian responses were similar. Luteinizing hormone (LH) and follicle stimulating hormone (FSH) rose to peak values within 48 h, and declined to hy-pogonadotropic levels within 2 weeks' time. Steroid levels showed a slight to marked rise after injection and fell to hypogonadal values within 1 week. LH suppression was maintained until the 8th week after the injection, while FSH levels rose to normal between the 3rd and 4th week. Estrogen secretion started to be restored in the course of the 7th and 8th week. Menses occurred between the 11th and 13 th week after the injection of the drug. This study demonstrates the possibility of rapid induction of a hypogonadotropic and hypogonadal condition in regularly cycling women by administration of a single triptorelin depot. Suppression of pituitary and ovarian function appears to be continued until the 8th week after the injection.

Original languageEnglish
Pages (from-to)153-161
Number of pages9
JournalGynecological Endocrinology
Volume6
Issue number3
DOIs
Publication statusPublished - 1 Jan 1992

Keywords

  • Depot Formulation
  • Luteinizing Hormone Releasing Hormone Agonist
  • Pituitary
  • Triptorelin

Fingerprint

Dive into the research topics of 'Pituitary and ovarian suppression after early follicular and midluteal administration of a lhrh agonist in a depot formulation: Decapeptyl cr'. Together they form a unique fingerprint.

Cite this